ACP
ITCI

Acuta Capital Partners’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Acuta Capital Partners’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-100,000
Closed -$3.43M – 43
2019
Q4 		$3.43M Buy
+100,000
New +$1.2M 0.85% 26

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Acuta Capital Partners's ITCI Position: Q2 2024 in Review

Acuta Capital Partners sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2024, closing a stake of 13,300 shares — an estimated $920K sold.

Acuta Capital Partners first reported a position in ITCI in Q4 2019 and held it in 2 quarters. The position peaked at $20.1M in Q4 2019. 376 funds tracked by Wall St. Rank hold ITCI as of Q2 2024.

  • Acuta Capital Partners reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2024 after selling out during the quarter.
  • Acuta Capital Partners sold 13,300 Intra-Cellular Therapies Inc. shares in Q2 2024, an estimated $920K.
  • Acuta Capital Partners first reported a position in Intra-Cellular Therapies Inc. in Q4 2019 and held it in 2 quarters.
  • Acuta Capital Partners's Intra-Cellular Therapies Inc. position peaked at $20.1M in Q4 2019.
  • 376 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2024.

Based on Acuta Capital Partners's 13F filing for Q2 2024, filed 14 Aug 2024.